

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allergan Aesthetics looks to further develop the Hybrid Injectables category by introducing its first dual-effect product, which combines the two active ingredients - hyaluronic acid, a well-known ingredient found in facial fillers and calcium hydroxyapa...
Product Name : Juvederm Volux XC
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Milton M. Hom
Deal Size : Inapplicable
Deal Type : Inapplicable
Tear Osmolarity Over Time With Artificial Tears
Details : HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
October 25, 2010
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Milton M. Hom
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hydroxyapatite vs Fluoride Toothpaste for MIH Remineralization
Details : Hydroxyapatite is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Molar Incisor Hypomineralisation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 16, 2025
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Alcon Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations
Details : HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
January 20, 2025
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Alcon Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins
Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.
Product Name : Tears Naturale Forte
Product Type : Carbohydrate
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Kalpna Kay Durairaj
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Calcium Hydroxylapatite on Cellulite Dimples in the Buttocks
Details : Calcium Hydroxyapatite is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cellulite.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Kalpna Kay Durairaj
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Merz Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational
Details : Calcium Hydroxylapatite is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 10, 2021
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Merz Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Innovative Luminera
Deal Size : Undisclosed
Deal Type : Acquisition
Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business
Details : Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.
Product Name : HArmonyCa
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 07, 2020
Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Innovative Luminera
Deal Size : Undisclosed
Deal Type : Acquisition

Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients
Details : HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
January 20, 2011
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Merz Aesthetics
Deal Size : Inapplicable
Deal Type : Inapplicable
Injectable Filler for Cheek Flattening
Details : Calcium Hydroxyapatite is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malar Deficiency.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 21, 2010
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Merz Aesthetics
Deal Size : Inapplicable
Deal Type : Inapplicable



